The DOI matches its Crossref record; 51 of the 56 references it cites were found in a registry or an index.
Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience
Abstract
CD20-targeted radioimmunotherapy is a promising new treatment for B-cell non-Hodgkin lymphoma (NHL). We now provide updated and long-term data on 59 chemotherapy-relapsed/refractory patients treated with iodine (131)I tositumomab in a phase I/II single-center study. Fifty-three patients received individualized therapeutic doses, delivering a specified total-body radiation dose (TBD) based on the clearance rate of a preceding dosimetric dose. Six patients received dosimetric doses only. Dose-escalations of TBD were conducted separately in patients who had or had not undergone a prior autologous stem cell transplant (ASCT) until a nonmyeloablative maximally tolerated TBD was established (non-ASCT = 75 cGy, post-ASCT = 45 cGy). Fourteen additional non-ASCT patients were treated with 75 cGy. Unlabeled antibody was given prior to labeled dosimetric and therapeutic doses to improve biodistribution. Forty-two (71%) of 59 patients responded; 20 (34%) had complete responses (CR). Thirty-five (83%) of 42 with low-grade or transformed NHL responded versus 7 (41%) of 17 with de novo intermediate-grade NHL (P =.005). For all 42 responders, the median progression-free survival was 12 months, 20.3 for those with CR. Seven patients remain in CR 3 to 5.7 years. Sixteen patients were re-treated after progression; 9 responded and 5 had a CR. Reversible hematologic toxicity was dose limiting. Only 10 patients (17%) had human anti-mouse antibodies detected. Long-term, 5 patients developed elevated thyroid-stimulating hormone levels, 5 were diagnosed with myelodysplasia and 3 with solid tumors. A single, well-tolerated treatment with iodine (131)I tositumomab can, therefore, produce frequent and durable responses in NHL, especially low-grade or transformed NHL. (Blood. 2000;96:1259-1266)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and in patients receiving 131 I-tositumomab (MTD 5 75 cGy, single administration in heavily pretreated patients without major marrow involvement with tumor) ( 92 , 93 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [93]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
Note on the Sampling Error of the Difference Between Correlated Proportions or Percentages
McNemar, Q. (1947) · Psychometrika · doi:10.1007/bf02295996 · Cited by 4,754
Fraker, P. J., & Speck, J. C. (1978) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(78)91322-0 · Cited by 4,553
The Non-Hodgkin's Lymphoma Pathologic Classification Project (1982) · Cancer · doi:10.1002/1097-0142(19820515)49:10 · Cited by 3,051
McLaughlin, P. J., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence‐Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,752
Characterization of a human B lymphocyte-specific antigen.
Stashenko, P., Nadler, L. M., Hardy, R., & Schlossman, S. F. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.4.1678 · Cited by 1,076
Research works printed but not linked: 7
- Maloney, 1996, The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines [abstract]., Blood., 88, 637a
- Kolstad, 1999, Characterization of the apoptotic process initiated by ligation of CD20 by the mouse monoclonal antibody Anti-B1 in the Burkitt's lymphoma cell line Ramos [abstract]., Blood., 94, 87a
- Wiseman, 1999, Therapeutic index of IDEC-Y2B8 radioimmunotherapy: up to 850 fold greater radiation dose to tumor than to normal organs [abstract]., Proc Am Soc Clin Oncol., 18, 4a
- Gates, 1998, Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy., J Nucl Med., 39, 1230
- Kaminski, 1997, A multicenter phase II study of Iodine-131 anti-B1 antibody (Bexxar) in patients with chemotherapy-relapsed/refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphoma [abstract]., Blood., 90, 509a
- Kaminski, 1998, Multicenter, phase III study of iodine-131 tositumomab (Anti-B1 Antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma [abstract]., Blood., 92, 316a
- Kaminski, 1997, Front-line treatment of advanced B-cell low-grade lymphoma with radiolabeled anti-B1 antibody: initial experience [abstract]., Am Soc Clin Oncol., 16, 51a
Cited by
Sorted by citations
Items 501–525 of 525
Wittig, B., Rieth, A., & Enghofer, E. (2006) · Springer eBooks · doi:10.1007/3-540-31303-6_45
Baum, R. P., Prasad, V., & Oliva, J. (2008) · Springer eBooks · doi:10.1007/978-3-540-28026-2_26
(2001) · Hematological Oncology · doi:10.1002/hon.672
Trümper, L. H. P., Mӧller, P., & Neubauer, A. (2004) · Springer eBooks · doi:10.1007/978-3-662-06670-6_71
Hochmaligne Non-Hodgkin-Lymphome
Hartmann, F., Schmits, R., & Pfreundschuh, M. G. (2007) · Springer eBooks · doi:10.1007/978-3-540-28978-4_22
Jacene, H. A., & Wahl, R. L. (2012) · Springer eBooks · doi:10.1007/978-0-387-48894-3_7
Zevalin®-Radioimmunotherapie (RIT) als neue Therapieoption bei follikulären B-Zell-Lymphomen
Herrmann, R. P., & Lohri, A. (2004) · Forum Médical Suisse ‒ Swiss Medical Forum · doi:10.4414/fms.2004.05357
(2004) · Cancer Investigation · doi:10.1081/cnv-120025338
Lee, C., Lim, I., Woo, S., Kim, W., Kim, K. I., Lee, K. C., Song, K., & Lim, S. M. (2020) · doi:10.21203/rs.3.rs-26393/v1
Laßmann, M. (2018) · Springer eBooks · doi:10.1007/978-3-662-54801-1_17
Gordon, S. M., Solimando, D. A., Waddell, J. A., & Durkin, R. J. (2004) · Hospital Pharmacy · doi:10.1177/001857870403900206
Therapeutic Antibodies and Immunologic Conjugates
Cheung, N. V. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50038-5
Dandapani, S. V., & Wong, J. Y. C. (2016) · doi:10.1002/9781119060727.ch16
Speer, T. W. (2012) · Springer eBooks · doi:10.1007/978-3-540-85516-3_286
Radionuclide Therapy of Lymphomas
Parihar, A. S., Jacene, H. A., Tirumani, S. H., & Wahl, R. L. (2022) · Springer eBooks · doi:10.1007/978-3-319-26067-9_47-3
Radionuclide Therapy of Lymphomas
Parihar, A. S., Jacene, H. A., Tirumani, S. H., & Wahl, R. L. (2022) · Springer eBooks · doi:10.1007/978-3-031-05494-5_47
Lue, J. K., & Cheson, B. D. (2024) · Wiley eBooks · doi:10.1002/9781119824572.ch3
Binding Promiscuity of Therapeutic Factor VIII
Reyes‐Ruiz, A., Bhale, A. S., Venkataraman, K., Dimitrov, J. D., & Lacroix‐Desmazes, S. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2358-0853
Design and Application of Nuclear and Molecular Theragnostic Probes
Sharma, D., Chaturvedi, S., Kaul, A., Pal, S., Singh, V. P., & Mishra, A. K. (2024) · ChemistrySelect · doi:10.1002/slct.202402204
Radioimmunotherapy (II): Clinical Application.
Cheon, G. J., Kang, H., & Lim, S.-M. (2006) · Nuclear Medicine and Molecular Imaging
Infections in Patients with Hematologic Malignancies Treated with Monoclonal Antineoplastic Therapy
Goy, A. H., & O'Brien, S. M. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-644-3_5
Magdelaine–Beuzelin, C. (2010) · theses.fr (ABES) · doi:10.70675/1eecbe7cz9002z472ez9df3zedc2100ebcb5
Retroviral-Mediated Gene Transfer for Engineering Tumor-Reactive T-Cells
Roszkowski, J. J., & Nishimura, M. I. (2006) · Humana Press eBooks · doi:10.1385/1-59745-011-1:213
Immunotoxin Therapy of Chronic Lymphocytic Leukemia
Frankel, A. E., & Kreitman, R. J. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-412-2_16
Metadata
- Authors
- Kaminski, M. S., Estes, J., Zasadny, K. R., Francis, I. R., Ross, C. W., Tuck, M., Regan, D., Fisher, S., Gutierrez, J., Kroll, S., Stagg, R., Tidmarsh, G., & Wahl, R. L.
- Affiliations
- University of Michigan (US)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2000-08-15
- Volume
- 96
- Issue
- 4
- Pages
- 1259-1266
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1573890015
- Cited by
- 525
- References
- 56
- Citations by year
- 2025: 1 · 2024: 9 · 2023: 7 · 2022: 7 · 2021: 4 · 2020: 13 · 2019: 7 · 2018: 7 · 2017: 11 · 2016: 15 · 2015: 14 · 2014: 17 · 2013: 14 · 2012: 21
- FWCI
- 41.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca056794-08)
- National Cancer Institute (R01-CA-56794, P01-CA-42678)
- National Center for Research Resources (M-01RR00042, M01RR000042)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- radioimmunotherapy, iodine-131 tositumomab, B-cell non-Hodgkin lymphoma, relapsed/refractory lymphoma, autologous stem cell transplantation, progression-free survival, complete response, long-term follow-up, hematologic toxicity, human anti-mouse antibodies, thyroid-stimulating hormone, myelodysplastic syndrome
- MeSH terms
- Adult, Aged, Antibodies, Monoclonal, Female, Follow-Up Studies, Humans, Iodine Radioisotopes, Male, Middle Aged, Recurrence, Lymphoma, B-Cell, Radioimmunotherapy, Treatment Outcome, Antigens, CD20
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
